查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1953536

放射性皮膚炎市場－全球產業規模、佔有率、趨勢、機會及預測（依產品、通路、地區及競爭格局分類，2021-2031年）

Radiodermatitis Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product (Topical, oral, dressings ), By Distribution Channel, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 182 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球放射性皮膚炎治療市場預計將從 2025 年的 4.8718 億美元成長到 2031 年的 5.8648 億美元，複合年成長率為 3.14%。

該市場由一系列專業產品組成，包括口服藥物、親水性敷料和外用製劑，旨在預防和控制癌症患者放射引起的皮膚反應。主要成長要素包括全球需要放射治療的癌症患者人數不斷增加，以及臨床上對實證支持治療以提高患者生活品質的日益關注。根據美國癌症協會 (ACS) 的報告，預計到 2025 年，美國將新增 2,041,910 例癌症病例，這將顯著增加易受輻射中毒影響的患者數量。

市場概覽
預測期 2027-2031
市場規模：2025年 4.8718億美元
市場規模：2031年 5.8648億美元
複合年成長率：2026-2031年 3.14%
成長最快的細分市場 局部的
最大的市場 北美洲

然而，市場擴張面臨許多障礙，包括先進創傷護理製劑的高昂成本，以及新興國家缺乏預防性皮膚治療的標準化報銷政策。這些經濟障礙限制了患者獲得優質治療方案的機會，並阻礙了注重成本的醫療保健系統採用高效產品。

市場促進因素

全球癌症發生率的不斷上升是全球放射性皮膚炎市場的主要促進因素。惡性腫瘤發生率的上升直接導致接受放射治療的患者人數增加。隨著癌症診斷數量的激增，用於應對常見副作用（例如放射引起的皮膚反應）的支持性護理也必須相應增加，從而擴大了需要預防性和治療性皮膚病護理的患者群體。根據世界衛生組織（WHO）國際癌症研究機構（IARC）於2024年2月發布的題為《全球癌症負擔日益加重》的新聞稿，預計到2050年，新增癌症病例將超過3500萬例，比2022年估計的2000萬例成長77%。

同時，市場正透過策略聯盟和產品系列擴張進行轉型，主要企業積極拓展其先進創傷護理產品線，以治療複雜的皮膚損傷。製造商正加大對高效配方和親水性敷料的投資，推動專業護膚領域收入的顯著成長。這一成長動能在近期發布的財務報告中可見一斑，例如康維特集團（ConvaTec Group）在2024年3月發布的報告顯示，其先進創傷護理部門在2023年實現了9.5%的有機收入成長，主要得益於抗菌藥物和生物製藥的推動。同樣，科樂普公司（Coloplast A/S）在2024年11月宣布，其先進創傷護理業務在2023/24會計年度實現了10%的內部成長，印證了全球對先進組織修復解決方案的強勁需求。

市場挑戰

全球放射性皮膚炎治療市場面臨許多成長障礙，主要原因是先進創傷護理製劑高成本且健保報銷政策不一致。雖然特製親水性敷料和外用藥物在控制放射性皮膚反應方面療效顯著，但其高昂的價格對注重成本的醫療機構而言構成了一道難以逾越的門檻。在許多地區，預防性皮膚治療不在強制性醫療保險的覆蓋範圍內，迫使患者自費或導致醫療機構不願儲備此類產品。這種經濟上的阻礙限制了患者獲得最佳治療的機會，並迫使醫療機構轉向價格更低的非專利藥，從而導致放射性皮膚炎專用產品的商業性分銷減少。

腫瘤科診療機構面臨的這種經濟負擔直接限制了高利潤輔助治療方案的採用。由於外部經濟壓力導致臨床預算收緊，非核心輔助產品的採購往往會減少。根據美國放射腫瘤學會2024年的數據，過去十年中，聯邦醫療保險（Medicare）對放射治療服務的累積報銷額下降超過20%，給治療中心帶來了巨大的財務壓力。這種嚴峻的報銷環境迫使診所盡可能降低營運成本，這直接抑制了高價值放射性皮膚炎治療產品的市場滲透，並阻礙了製造商的收入成長。

市場趨勢

全球放射性皮膚炎治療市場正日益青睞光生物調節療法（PBMT）來控制症狀。傳統的局部治療正逐漸被基於光的組織再生技術所取代。這一轉變源於PBMT能夠從細胞層面減輕炎症，從而在放射性皮膚毒性發展為開放性傷口之前，限制其嚴重程度。臨床驗證證實PBMT在維持高劑量放射治療期間皮膚完整性的有效性，加速了其應用。一項題為「光生物調節療法對癌症患者急性放射性皮膚炎的影響」的研究於2024年10月發表在《放射治療與腫瘤學》雜誌上，該研究發現，PBMT顯著降低了嚴重皮膚反應的負擔，與標準對照組相比，2級和3級皮膚炎的風險降低了0.36倍。

同時，成膜凝膠技術，尤其是矽基屏障膜，正迅速普及。這些技術旨在提供比傳統水基乳膏更好的預防性保護，形成半封閉、自乾的保護層，模擬角質層。這可以防止經表皮水分流失，且避免了厚重藥膏引起的浸漬風險。這項創新技術能夠在不干擾放射治療的情況下提供持續的皮膚保護，因此在腫瘤中心得到了更廣泛的應用。根據發表於2024年9月《癌症支持治療》雜誌上題為「StrataXRT用於預防乳癌急性放射性皮膚炎」的論文，使用這些先進的屏障凝膠顯著減少了放射治療期間的濕性脫屑，僅有23.3%的患者出現這種情況。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球放射性皮膚炎市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依產品分類（外用藥物（皮質類固醇、親水性乳膏、抗生素等）、口服藥物、敷料（水凝膠及親水膠體敷料、無線屏障膜、蜂蜜浸漬紗布、矽塗層敷料等））
    • 按分銷管道（醫院藥房、零售藥房、網路藥房）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

6. 北美放射性皮膚炎市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

7. 歐洲放射性皮膚炎市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

8. 亞太地區放射性皮膚炎市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

9. 中東和非洲放射性皮膚炎市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲放射性皮膚炎市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進要素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

第13章 全球放射性皮膚炎市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的可能性
  • 供應商電力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • 3M Company
  • Bausch Health Companies Inc.
  • Bayer AG
  • BMG PHARMA SpA
  • Charles River Laboratories International Inc.
  • ConvaTec Group plc
  • Helsinn Healthcare SA
  • ICON plc
  • Integra LifeSciences
  • Molnlycke Health Care AB
  • Stratpharma AG

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 20091

The Global Radiodermatitis Market is projected to expand from USD 487.18 Million in 2025 to USD 586.48 Million by 2031, reflecting a compound annual growth rate of 3.14%. This market consists of a specialized portfolio of oral pharmaceuticals, hydrophilic dressings, and topical agents aimed at preventing or managing radiation-induced skin reactions in oncology patients. The primary growth drivers include the increasing global prevalence of cancer necessitating radiotherapy and a heightened clinical focus on evidence-based supportive care to enhance patient quality of life. As reported by the American Cancer Society, a total of 2,041,910 new cancer cases are expected in the United States in 2025, which significantly enlarges the patient population susceptible to radiation toxicity.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 487.18 Million
Market Size 2031USD 586.48 Million
CAGR 2026-20313.14%
Fastest Growing SegmentTopical
Largest MarketNorth America

However, market expansion faces a substantial obstacle in the form of prohibitive costs for advanced wound care formulations and a lack of standardized reimbursement policies for prophylactic dermatological treatments in emerging economies. These financial barriers restrict patient access to premium management solutions and limit the adoption of higher-efficacy products within cost-sensitive healthcare systems.

Market Driver

The rising global incidence of cancer acts as the primary engine driving the Global Radiodermatitis Market, as higher rates of malignancy directly lead to an increased number of patients undergoing radiation therapy. This surge in cancer diagnoses requires a proportional increase in supportive care interventions to handle common side effects like radiation-induced skin reactions, resulting in a growing patient pool that needs prophylactic and therapeutic dermatological management. According to the World Health Organization's International Agency for Research on Cancer (IARC) in their February 2024 press release 'Global cancer burden growing', new cancer cases are predicted to exceed 35 million by 2050, marking a 77% increase from the estimated 20 million cases in 2022.

At the same time, the market is being transformed by strategic collaborations and product portfolio expansions, with key industry players actively diversifying their advanced wound care offerings to treat complex skin injuries. Manufacturers are investing heavily in high-efficacy formulations and hydrophilic dressings, which is driving significant revenue growth in the specialized skincare sector. This momentum is highlighted in recent financial reports; for instance, Convatec Group Plc reported in March 2024 that its Advanced Wound Care category achieved 9.5% organic revenue growth in 2023, fueled by antimicrobials and biologics. Similarly, Coloplast A/S announced in November 2024 that its Advanced Wound Care business saw 10% organic growth for the 2023/24 year, underscoring the strong global demand for advanced tissue repair solutions.

Market Challenge

The Global Radiodermatitis Market encounters a significant barrier to growth due to the high costs of advanced wound care formulations and the lack of consistent reimbursement policies. Although specialized hydrophilic dressings and topical agents provide superior efficacy in managing radiation-induced skin reactions, their premium pricing creates a steep entry barrier for cost-sensitive healthcare systems. In many regions, prophylactic dermatological treatments are not covered by essential insurance, forcing patients to pay out-of-pocket or causing clinics to avoid stocking these items. This economic friction limits patient access to optimal care and compels providers to rely on cheaper, generic alternatives, thereby reducing the commercial volume of specialized radiodermatitis products.

This financial strain on oncology practices directly restricts the adoption of high-margin supportive care solutions. As clinical budgets tighten due to external economic pressures, the purchase of non-core ancillary products is often curtailed. Data from the American Society for Radiation Oncology in 2024 indicates that cumulative Medicare reimbursement reductions for radiation therapy services have exceeded 20% over the last decade, placing immense fiscal pressure on treatment centers. This difficult reimbursement environment forces clinics to minimize operational spending, which directly hampers the market penetration of premium radiodermatitis treatments and stalls revenue growth for manufacturers.

Market Trends

The Global Radiodermatitis Market is increasingly adopting Photobiomodulation Therapy (PBMT) for symptom management, moving from solely topical interventions to light-based tissue regeneration methods. This shift is driven by the therapy's ability to reduce inflammation at the cellular level, thereby lessening the severity of radiation-induced skin toxicity before it progresses to open wounds. Adoption is accelerating as clinical bodies confirm its efficacy in preserving skin integrity during high-dose radiation schedules. A study published in Radiotherapy and Oncology in October 2024, titled 'Effects of photobiomodulation therapy for acute radiation dermatitis in patients with cancer', found that this therapy significantly reduced the burden of severe skin reactions, showing a risk difference of -0.36 for grade 2 and 3 dermatitis compared to standard control groups.

Concurrently, there is a rapid expansion of film-forming gel technologies, particularly silicone-based barrier films, which are designed to offer better prophylactic protection than traditional aqueous creams. These formulations create a semi-occlusive, self-drying shield that mimics the stratum corneum, preventing transepidermal water loss without the risk of maceration associated with heavy ointments. This innovation allows for continuous skin protection that does not interfere with radiation delivery, leading to higher utilization rates in oncology centers. According to an article in Supportive Care in Cancer from September 2024 titled 'StrataXRT for the prevention of acute radiation dermatitis in breast cancer', the use of these advanced barrier gels resulted in substantial preventative efficacy, with only 23.3% of treated patients developing moist desquamation during the radiotherapy course.

Key Market Players

  • 3M Company
  • Bausch Health Companies Inc.
  • Bayer AG
  • BMG PHARMA S.p.A.
  • Charles River Laboratories International Inc.
  • ConvaTec Group plc
  • Helsinn Healthcare SA
  • ICON plc
  • Integra LifeSciences
  • Molnlycke Health Care AB
  • Stratpharma AG

Report Scope

In this report, the Global Radiodermatitis Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Radiodermatitis Market, By Product

  • Topical(Corticosteroids, Hydrophilic Creams, Antibiotics, Others)
  • Oral
  • Dressings (Hydrogel and Hydrocolloid Dressings, No Sting Barrier Film, Honey Impregnated Gauze, Silicone Coated Dressings, Others)

Radiodermatitis Market, By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Radiodermatitis Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Radiodermatitis Market.

Available Customizations:

Global Radiodermatitis Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Radiodermatitis Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product (Topical(Corticosteroids, Hydrophilic Creams, Antibiotics, Others), oral, dressings (Hydrogel and Hydrocolloid Dressings, No Sting Barrier Film, Honey Impregnated Gauze, Silicone Coated Dressings, Others))
    • 5.2.2. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Radiodermatitis Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product
    • 6.2.2. By Distribution Channel
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Radiodermatitis Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product
        • 6.3.1.2.2. By Distribution Channel
    • 6.3.2. Canada Radiodermatitis Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product
        • 6.3.2.2.2. By Distribution Channel
    • 6.3.3. Mexico Radiodermatitis Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product
        • 6.3.3.2.2. By Distribution Channel

7. Europe Radiodermatitis Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
    • 7.2.2. By Distribution Channel
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Radiodermatitis Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product
        • 7.3.1.2.2. By Distribution Channel
    • 7.3.2. France Radiodermatitis Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product
        • 7.3.2.2.2. By Distribution Channel
    • 7.3.3. United Kingdom Radiodermatitis Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product
        • 7.3.3.2.2. By Distribution Channel
    • 7.3.4. Italy Radiodermatitis Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product
        • 7.3.4.2.2. By Distribution Channel
    • 7.3.5. Spain Radiodermatitis Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product
        • 7.3.5.2.2. By Distribution Channel

8. Asia Pacific Radiodermatitis Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
    • 8.2.2. By Distribution Channel
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Radiodermatitis Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product
        • 8.3.1.2.2. By Distribution Channel
    • 8.3.2. India Radiodermatitis Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product
        • 8.3.2.2.2. By Distribution Channel
    • 8.3.3. Japan Radiodermatitis Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product
        • 8.3.3.2.2. By Distribution Channel
    • 8.3.4. South Korea Radiodermatitis Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product
        • 8.3.4.2.2. By Distribution Channel
    • 8.3.5. Australia Radiodermatitis Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product
        • 8.3.5.2.2. By Distribution Channel

9. Middle East & Africa Radiodermatitis Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product
    • 9.2.2. By Distribution Channel
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Radiodermatitis Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product
        • 9.3.1.2.2. By Distribution Channel
    • 9.3.2. UAE Radiodermatitis Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product
        • 9.3.2.2.2. By Distribution Channel
    • 9.3.3. South Africa Radiodermatitis Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product
        • 9.3.3.2.2. By Distribution Channel

10. South America Radiodermatitis Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product
    • 10.2.2. By Distribution Channel
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Radiodermatitis Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product
        • 10.3.1.2.2. By Distribution Channel
    • 10.3.2. Colombia Radiodermatitis Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product
        • 10.3.2.2.2. By Distribution Channel
    • 10.3.3. Argentina Radiodermatitis Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product
        • 10.3.3.2.2. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Radiodermatitis Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. 3M Company
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Bausch Health Companies Inc.
  • 15.3. Bayer AG
  • 15.4. BMG PHARMA S.p.A.
  • 15.5. Charles River Laboratories International Inc.
  • 15.6. ConvaTec Group plc
  • 15.7. Helsinn Healthcare SA
  • 15.8. ICON plc
  • 15.9. Integra LifeSciences
  • 15.10. Molnlycke Health Care AB
  • 15.11. Stratpharma AG

16. Strategic Recommendations

17. About Us & Disclaimer